Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - SARS-CoV-2 and cancer 1

1670O - Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium

Date

19 Sep 2020

Session

Proffered Paper - SARS-CoV-2 and cancer 1

Presenters

Carlo Palmieri

Citation

Annals of Oncology (2020) 31 (suppl_4): S934-S973. 10.1016/annonc/annonc289

Authors

C. Palmieri1, L. Turtle2, A. Docherty3, E. Harrison3, T. Drake4, B. Greenhalf5, P.J. Openshaw6, J.K. Baillie7, M.G. Malcolm G Semple8

Author affiliations

  • 1 Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, L7 8YA - Liverpool/GB
  • 2 Tropical D Infectious Disease Unit., Liverpool University Hospitals NHS Foundation Trust., L7 8YA - Liverpool/GB
  • 3 Usher Institute, University of Edinburgh, EH8 9YL - Edinburgh/GB
  • 4 Dept Of Clinical Surgery, University of Edinburgh, EH8 9YL - Edinburgh/GB
  • 5 Molecular And Clinical Cancer Medicine, University of Liverpool, L69 3BX - Liverpool/GB
  • 6 National Heart And Lung Division,, Imperial College London, SW3 6LY - London/GB
  • 7 Roslin Institute, University of Edinburgh, EH25 9PS - Edinburgh/GB
  • 8 University Of Liverpool, NIHR Health Protection Unit in Emerging and Zoonotic infections and Centre for Excellence in Infectious Disease Research, L69 7BE - Liverpool/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1670O

Background

The SARS-CoV-2 pandemic in the UK triggered a national characterisation protocol and information on co-morbidities including malignant neoplasm is recorded. A lack of prospective data regarding cancer patients with COVID-19 hampers the development of an evidence based approach in this population. The Clinical Characterisation Protocol-CANCER-UK is a UK multi-disciplinary project aimed at characterising the presentation and course of COVID-19 in cancer patients with the aim of informing practice.

Methods

The international Severe Acute Respiratory and emerging Infections Consortium (ISARIC)-4C COVID-19 Clinical Information Network (CO-CIN) collects data on hospital inpatients with proven/high likelihood of COVID-19. Data was collected in 166 UK sites using a questionnaire adopted by the WHO. Data on patients with malignant neoplasm was extracted from the main dataset. We chose a priori to restrict any analysis of outcome to patients who were admitted more than 14 days before data extraction (13th May 2020).

Results

As of 13th May 2020 1797 of 16160 participants had malignant neoplasm (8.6% of all cases). Age<50 62 (3.5%), 50-60 378 (21%), 70-79 558 (31%), 80+ 1002 (42%). Male 1147 (64%); Female 645 (36%). Commonest comorbidities chromic pulmonary disease (22%), chronic kidney disease (21%), uncomplicated diabetes (19%) and dementia (14%). Outcomes 35% discharged alive, 30% care ongoing & 35% died. Admiited to ICU: 150 cases (25% discharged alive,31% care ongoing & 45% died). Receiving invasive ventiation: 67 cases (18% discharged alive, 25% care ongoing:25% & 57% died). HR mortality for malignancy (adjusted for age, sex, other comorbidity): 1.13 (1.02-1.24, p=0.017). Data on presentation will be presented.

Conclusions

Europe’s largest prospective COVID-19 dataset demonstrates that cancer is independently associated with mortality in patients admitted with COVID-19. Data collection is on-going and updated data will be presented including a comparison of cancer vs. non-cancer cohort with regard to presentation, comorbidity and otucomes.

Clinical trial identification

ISRCTN66726260.

Editorial acknowledgement

No editorial assistance was received.

Legal entity responsible for the study

and international Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Coronavirus Clinical Characterisation Consortium (ISARIC4C).

Funding

UK Research and Innovation, Medical Research Council and Department for Health and Social Care.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings